Scholarlink

<p>CD3 bispecific antibodies (BsAbs) targeting delta-like ligand 3 (DLL3) have emerged as promising candidates in cancer immunotherapy by enabling T-cell-mediated tumor lysis. A critical unmet need is to establish structural correlates of their preclinical activity and clinical efficacy to guide rational drug optimization. This study systematically characterized three clinical-stage CD3×DLL3 BsAbs, Tarlatamab (AMG757), BI764532 and HPN328, via structural modeling, T-cell activation assays, cytokine profiling, and tumor cytotoxicity tests. Preclinical data were further correlated with clinical trial outcomes to verify the predictive value of in vitro models. Preclinical data demonstrate a strong correlation with clinical outcomes, confirming that in vitro assays can reliably predict therapeutic response. Notably, structural features including immune synapse (IS) distance and epitope binding are tightly correlated with efficacy and safety. HPN328 exhibited the most potent T-cell activation and tumor killing activity, which aligned with its clinical confirmed complete response rate (cORR) of 50% in small cell lung cancer. BI764532 demonstrated a balanceed efficacy (ORR 18% in SCLC), while Tarlatamab achieved an ORR range of 13–40% across clinical trials. IS distance and epitope binding are strongly correlated with efficacy and safety of DLL3-targeted BsAbs, providing a critical framework for optimizing T-cell engager design in cancer immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy

  • 期刊论文

  • 发表日期：

    2026年2月7日

查看全文
  • Shanshan Chen,
  • Guangshun Zhang,
  • Xiangyi He,
  • Yuze Li,
  • Dong Li

摘要

CD3 bispecific antibodies (BsAbs) targeting delta-like ligand 3 (DLL3) have emerged as promising candidates in cancer immunotherapy by enabling T-cell-mediated tumor lysis. A critical unmet need is to establish structural correlates of their preclinical activity and clinical efficacy to guide rational drug optimization. This study systematically characterized three clinical-stage CD3×DLL3 BsAbs, Tarlatamab (AMG757), BI764532 and HPN328, via structural modeling, T-cell activation assays, cytokine profiling, and tumor cytotoxicity tests. Preclinical data were further correlated with clinical trial outcomes to verify the predictive value of in vitro models. Preclinical data demonstrate a strong correlation with clinical outcomes, confirming that in vitro assays can reliably predict therapeutic response. Notably, structural features including immune synapse (IS) distance and epitope binding are tightly correlated with efficacy and safety. HPN328 exhibited the most potent T-cell activation and tumor killing activity, which aligned with its clinical confirmed complete response rate (cORR) of 50% in small cell lung cancer. BI764532 demonstrated a balanceed efficacy (ORR 18% in SCLC), while Tarlatamab achieved an ORR range of 13–40% across clinical trials. IS distance and epitope binding are strongly correlated with efficacy and safety of DLL3-targeted BsAbs, providing a critical framework for optimizing T-cell engager design in cancer immunotherapy.